Understanding exactly when and where Alzheimer's pathology becomes detectable — and measurable — has enormous consequences for the timing of interventions. New findings from a multi-cohort PET imaging study reframe how clinicians and researchers should think about tau as a biomarker, suggesting that what you measure matters as much as when you measure it.
Using positron emission tomography data pooled across four independent longitudinal cohorts, Macedo and colleagues tracked how tau pathology evolves through Alzheimer's disease stages along two distinct dimensions: spatial extent (how widely tau has spread across brain regions) and tau load (the intensity or density of tau accumulation within affected areas). The analysis reveals a dissociation between these metrics over disease course. Spatial extent metrics proved more sensitive during early-stage disease, capturing the initial propagation of tau across brain networks before clinical symptoms dominate. By contrast, tau load metrics — the sheer burden of pathological tau — became the more informative signal in later, more advanced disease stages when neurodegeneration is well underway.
This two-phase model carries meaningful implications for the broader Alzheimer's biomarker field. Current staging frameworks, including the recently revised AT(N) biological definition, rely heavily on threshold-based classifications that may conflate these two fundamentally different dynamics. If extent and load diverge in their trajectories, clinical trials enrolling participants based on tau-positive PET scans could be inadvertently mixing early-propagators with late-burden cases — diluting treatment effect estimates. From a screening standpoint, the finding that spatial spread precedes load escalation suggests that extent-sensitive metrics could sharpen detection windows for secondary prevention trials. The multi-cohort design strengthens generalizability, though replication across diverse ethnic populations remains an important next step. This is a methodologically rigorous, potentially practice-shaping contribution to Alzheimer's staging science.